Apoptotic killing of HIV-1-infected macrophages is subverted by the viral envelope glycoprotein

PLoS Pathog. 2007 Sep 7;3(9):1281-90. doi: 10.1371/journal.ppat.0030134.

Abstract

Viruses have evolved strategies to protect infected cells from apoptotic clearance. We present evidence that HIV-1 possesses a mechanism to protect infected macrophages from the apoptotic effects of the death ligand TRAIL (tumor necrosis factor-related apoptosis-inducing ligand). In HIV-1-infected macrophages, the viral envelope protein induced macrophage colony-stimulating factor (M-CSF). This pro-survival cytokine downregulated the TRAIL receptor TRAIL-R1/DR4 and upregulated the anti-apoptotic genes Bfl-1 and Mcl-1. Inhibition of M-CSF activity or silencing of Bfl-1 and Mcl-1 rendered infected macrophages highly susceptible to TRAIL. The anti-cancer agent Imatinib inhibited M-CSF receptor activation and restored the apoptotic sensitivity of HIV-1-infected macrophages, suggesting a novel strategy to curtail viral persistence in the macrophage reservoir.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis / drug effects*
  • Benzamides
  • Gene Products, env / physiology*
  • HIV Infections / pathology*
  • HIV-1*
  • Humans
  • Imatinib Mesylate
  • Macrophage Colony-Stimulating Factor / biosynthesis*
  • Macrophages / virology*
  • Piperazines / pharmacology
  • Pyrimidines / pharmacology
  • Receptors, TNF-Related Apoptosis-Inducing Ligand / biosynthesis*

Substances

  • Benzamides
  • Gene Products, env
  • Piperazines
  • Pyrimidines
  • Receptors, TNF-Related Apoptosis-Inducing Ligand
  • Macrophage Colony-Stimulating Factor
  • Imatinib Mesylate